Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Medtronic
UBS
Boehringer Ingelheim
Cantor Fitzgerald
Chinese Patent Office
Teva
Fish and Richardson
US Department of Justice
Citi
Merck

Generated: October 19, 2017

DrugPatentWatch Database Preview

Claims for Patent: 5,547,948

« Back to Dashboard

Claims for Patent: 5,547,948

Title: Controlled release of steroids from sugar coatings
Abstract:A sugar coating composition for application to a compressed medicinal tablet comprising a sugar, a dose of a hormonal steroid and a steroid release rate controlling amount of microcrystalline cellulose.
Inventor(s): Barcomb; Reginald J. (Mooers Forks, NY)
Assignee: American Home Products Corporation (Madison, NJ)
Application Number:08/373,667
Patent Claims: 1. A compressed tablet comprising a tablet core containing conjugated estrogens and a sugar coating in which said sugar coating incorporates a hormonal steroid and a release rate controlling amount of microcrystalline cellulose.

2. A compressed tablet of claim 1 in which said tablet core contains from about 0.1 to about 5.0 milligrams of conjugated estrogens and said sugar coating contains from about 1.0 to about 50 milligrams of said hormonal steroid.

3. A compressed tablet of claim 1 in which said tablet core contains from about 0.3 to about 2.5 milligrams of conjugated estrogens and said sugar coating contains about 1.5 to about 30 milligrams of medroxyprogesterone acetate.

4. A compressed tablet comprising a tablet core containing conjugated estrogens and a sugar coating in which said sugar coating incorporates with the sugar sucrose, the hormonal steroid medroxyprogesterone acetate and asteroid release rate controlling amount of microcrystalline cellulose.

5. A compressed tablet of claim 4 in which said tablet core contains from about 0.1 to about 5.0 milligrams of conjugated estrogens and said sugar coating contains from about 1 to about 50 milligrams of medroxyprogesterone acetate.

6. A compressed tablet of claim 4 in which said tablet core contains from about 0.3 to about 2.5 milligrams of conjugated estrogens and said sugar coating contains about 2.5 to about 30 milligrams of medroxyprogesterone acetate.
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving leading biopharmaceutical companies globally:

Mallinckrodt
Farmers Insurance
Novartis
AstraZeneca
Citi
Medtronic
Merck
Cipla
Chinese Patent Office
Baxter

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot